澳门大学陈新教授课题组2019年招收硕士（含推免）研究生、博士（含直博）研究生、研究助理及博士后研究员
澳门大学陈新教授 (Professor Xin Chen) 课题组2019年招收硕士（含推免）研究生，博士（含直博）研究生, 博士后研究员
要求： 具有生物、医药相关学科学位，熟悉动物实验及细胞操作技术，具有免疫学背景优先。对科学研究有强烈兴趣，为人诚信，工作勤奋，善于沟通，有独立思考及工作能力，博士后及博士生申请者需有发表SCI文章经验，英文水平需要符合澳门大学要求。
研究方向： 免疫调节机制及免疫药理
澳门大学2019/2020学年招收推荐免试硕士、博士（直接读博）研究生
https://www.umac.mo/grs/cn/admissions.php
澳大博士生助学金
博士生助学金的资助来自大学经费或导师的科研经费。获得博士生助学金之学生可获每月澳门币12,500元(最高可达澳门币14,000元)的津贴。
澳大博士生助学金详情https://www.umac.mo/grs/cn/admissions_phd_assistantship.php
澳大濠江博士生奖学金
获颁此奖学金之博士研究生获每月澳门币2万元的津贴，及每学年最多澳门币1万元的会议或研究活动交通津贴，为期最长四年。
澳大濠江博士生奖学金详情https://www.umac.mo/grs/cn/admissions_scholarship.php
澳大濠江博士后奖学金
两年总奖学金澳门币100万
1. Monthly remuneration of MOP40,000 (taxable).
2. Annual conference and research related trips allowance of MOP20,000.
3. Maximum contract period of 2 years*.
澳大濠江博士后奖学金详情https://www.umac.mo/research/pag ... ication%202018.html
高校博士后专项资助计划(澳门)
资助名额: 50名
每月津贴: 40,000.00 Mop (RMB35000)
资助期：最长24个月
高校博士后专项资助计划(澳门)详情
http://www.fdct.gov.mo/zh_tw/postdoc.html
联系方式： 欢迎直接联系陈新教授(Professor Xin Chen)（xchen@umac.mo）。
申请方式：网上报名，具体报名及招生要求请参阅澳门大学研究生院网页（http://www.umac.mo/grs/cn/admissions.php）
Selective recent publications (* corresponding or co-corresponding author):
1.He, T., S. Liu, S. Chen, J. Ye, X. Wu, Z. Bian and X. Chen (2018). "The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4+Foxp3+ Regulatory T Cells." Frontiers in Immunology 9(1556).
2.Zou, H., R. Li, H. Hu, Y. Hu and X. Chen (2018). "Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents." Frontiers in Immunology 9(594).
3.Nie, Y., J. He, H. Shirota, A. L. Trivett, Yang, D. M. Klinman, J. J. Oppenheim and X. Chen (2018). "Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer." Sci Signal 11(511).
4.Liu, S. and X. Chen (2018). "Dietary therapy may be sufficient for type 1 diabetes treatment." Cell Mol Immunol 15(2): 85-87.
5.Li, P., Y. Zheng and X. Chen (2017). "Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics." Front Pharmacol 8: 460.
6.Chen, X. and J. J. Oppenheim (2017). "Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer." Sci Signal 10(462).
7.Nie, Y., Yang, A. Trivett, Z. Han, H. Xin, X. Chen and J. J. Oppenheim (2017). "Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors." Sci Rep 7(1): 14186.
8.Chen, X. and J. J. Oppenheim (2016). "Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity." Nat Rev Rheumatol 12(11): 625-626.
9.Zaragoza, B., X. Chen, J. J. Oppenheim, A. Baeyens, S. Gregoire, D. Chader, G. Gorochov, M. Miyara and B. L. Salomon (2016). "Suppressive activity of human regulatory T cells is maintained in the presence of TNF." Nat Med 22(1): 16-17.
10.Yan, F., R. Du, F. Wei, H. Zhao, J. Yu, C. Wang, Z. Zhan, T. Ding, X. Ren, X. Chen and H. Li (2015). "Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients." Cancer Immunol Immunother 64(11): 1475-1485.
11.Hamano, R., X. Wu, Y. Wang, J. J. Oppenheim and X. Chen (2015). "Characterization of MT-2 cells as a human regulatory T cell-like cell line." Cell Mol Immunol 12(6): 780-782.
12.Chen, X., J. Willette-Brown, X. Wu, Y. Hu, O. M. Howard, Y. Hu and J. J. Oppenheim (2015). "IKKalpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells." FASEB J 29(2): 443-454.
PI学术背景，请参见：
https://sklqrcm.umac.mo/xinchen/
澳门大学新校区，请参见： http://www.umac.mo/co/gallery.php#ad-image-0
发自小木虫Android客户端 |
回复此楼
10+4
